From NAMS 2021: The truth about aspirin and statin prescription for CVD prevention


Margo B. Minissian, PhD, shares key updates from the newest recommendations for primary prevention of cardiovascular disease in women from the ACC and AHA. Minissian is executive director, Geri & Richard Brawerman Nursing Institute at Cedars-Sinai Medical Center and the Simms/ Mann Endowed Chair of Nursing Education, Innovation and Research at Cedars-Sinai Medical Center.

Cardiovascular disease (CVD) remains the leading cause of morbidity for women in the United States. Prior to the update in 2020, published in the Journal of the American College of Cardiology, there had been no formal guidelines from the American College of Cardiology (ACC)/American Heart Association (AHA) specifically addressing CVD in women since 2011.

In her presentation at the North American Menopause Society’s (NAMS) 2021 Annual Meeting, Minissian discussed the update’s critical topics related to risk factors and treatments that have led to controversies and confusion.

Related Videos
Hot flashes poorly impact sleep quality | Image Credit:
What's new in endometrium care? | Image Credit:
How to manage bone health in midlife women | Image Credit: -
Mary Jane Minkin, MD, discusses The Menopause Society 2023 Annual Meeting | Image Credit: Yale School of Medicine
Highlights from The Menopause Society 2023 Annual Meeting  | Image Credit:
How fezolinetant changes management of hot flashes | Image Credit:
Fezolinetant effective against vasomotor symptoms | Image Credit:
Gloria Richard-Davis MD, MBA, NCMP, FACOG
Related Content
© 2023 MJH Life Sciences

All rights reserved.